348 Studies Now Enrolling
Menu
Search
Medical Condition
Displaying 1 - 6 of 6
Condition: COVID-19 (Coronavirus)
Investigator: Elizabeth Oelsner, MD, MPH
Status: Currently Recruiting
This study is called the COVID-19 Lung Microvascular and Parenchymal Sequelae (LUNG MaPS) Study. The purpose of the study is to learn about the effects of COVID-19 infections on the lungs and heart, and to improve our understanding of why some COVID-19 patients…
Condition: COVID-19 (Coronavirus)
Investigator: Elisa Konofagou, PhD
Status: Closed
An ultrasound imaging study to assess the long terms effect of past COVID-19 infection in the heart, lung and vessels of recovered patients.
Condition: COVID-19 (Coronavirus)
Investigator: Christine Kim Garcia, MD
Status: Closed
Have you recovered from COVID-19 pneumonia? The FAR-ILD study is designed to detect and study the earliest stages of ILD in at-risk adults, including those who have had a severe viral pneumonia. FAR-ILD is a non-interventional study. This means that FAR-ILD is not involved in testing any new interventions or therapies. The purpose of FAR-ILD is to gather…
Condition: Allergy, Asthma, & Immunology / Asthma
Investigator: Meyer Kattan, MD
Status: Currently Recruiting
We are interested in learning more about these diseases and how to treat them. Our research program is conducting several studies including: a study to learn if treatment with a drug named dupilumab can help reduce asthma attacks in children, a study to observe a specific type of irritation in the lungs and how it relates to…
Condition: Allergy, Asthma, & Immunology / Asthma
Investigator: Joyce Yu, MD
Status: Closed
This study is designed to examine the efficacy and safety profile of dupilumab over one year in a population of asthmatic children in need for an additional treatment to their current maintenance management. Patients are randomized to either dupilumab or matching placebo administered standard care for a maximum treatment duration of 52 weeks. The…
Condition: Allergy, Asthma, & Immunology / Asthma
Investigator: Joyce Yu, MD
Status: Closed
The purpose of this global study is to provide evidence of the efficacy and safety of 210 mg dose of tezepelumab administered every 4 weeks subcutaneously in adults and adolescents (12 years of age and older) with a history of asthma exacerbations and severe uncontrolled asthma receiving medium or high dose inhaled corticosteroids plus at least one…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE